Cromos Pharma, where the patients are

United States

Kurt+Peter Foundation builds online patient registry for muscular dystrophy

Wednesday, December 18, 2013 01:49 PM

The Kurt+Peter Foundation, a nonprofit group that supports research into potential therapies, has released the first patient registry for Limb Girdle Muscular Dystrophy, type 2C, also known as gamma sarcoglycanopathy (LGMD2C). 

More... »

CRF Health eCOA webinar series

NIH launches regional Stroke Trials Network

Wednesday, December 18, 2013 01:39 PM

The National Institutes of Health has launched a network of 25 regional stroke centers working with nearby satellite facilities spanning the country. They will include teams of researchers representing every medical specialty needed for stroke care and will address the three prongs of stroke research: prevention, treatment and recovery.

More... »

CIRM funds $61 million through Disease Team awards

Wednesday, December 18, 2013 08:01 AM

Reflecting the progress being made in moving the most promising therapies out of the lab and into clinical trials, the state stem cell agency the California Institute for Regenerative Medicine (CIRM) has approved $61 million in funding for its third round of Disease Team awards. The funding was approved by the stem cell agency's governing board, the Independent Citizen's Oversight Committee (ICOC).

More... »

PixarBio opens new headquarters, R&D center

Monday, December 16, 2013 02:17 PM

PixarBio has signed a five-year lease agreement for its new corporate headquarters and research center to be located in Medford, Mass. The facility will house state-of-the-art chemical, bio and tissue labs. The company also will move its corporate headquarters to the Medford, Mass., facility from Salem, N.H.

More... »

FDA approves first generic versions of antidepressant drug Cymbalta

Friday, December 13, 2013 01:41 PM

The FDA has approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions.

More... »

GSK's FluLaval Quadrivalent effective in preventing pediatric seasonal flu

Friday, December 13, 2013 01:29 PM

A peer-reviewed study issued online by the New England Journal of Medicine has reported that GlaxoSmithKline's FluLaval Quadrivalent reduced flu cases among children ages three to eight by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%. This was the first large-scale clinical trial conducted specifically to review the safety and effectiveness of vaccinating children with a four-strain flu vaccine. The randomized, controlled clinical trial included 5,220 children and was one of the pivotal studies leading to the recent approval of FluLaval Quadrivalent by the FDA.

More... »

FDA approves first drug treatment for Peyronie’s disease

Friday, December 13, 2013 01:10 PM

The FDA has approved a new use for Xiaflex (collagenase clostridium histolyticum) as the first FDA-approved medicine to treat men with bothersome curvature of the penis, a condition known as Peyronie’s disease.

More... »

Agilux Laboratories expands in vivo pharmacokinetics services

Monday, December 9, 2013 12:32 PM

New England-based CRO Agilux Laboratories, a provider of drug metabolism and pharmacokinetics (DMPK) services to sponsors, has expanded its in vivo pharmacokinetics services to support clients' demands and increased service requirements. The space expansion will allow Agilux to significantly increase its capacity and volume, while maintaining fast study starts.

More... »

AstraZeneca donates Brixham Environmental Laboratory to Plymouth University

Monday, December 9, 2013 12:25 PM

AstraZeneca will donate its Environmental Laboratory in Brixham to Plymouth University to ensure the lab continues to serve scientific and research purposes.

More... »

Sarah Cannon Research Institute acquires Clinical Development Group

Friday, December 6, 2013 12:59 PM

Sarah Cannon Research Institute (SCRI), a global strategic research organization, has acquired Clinical Development Group (CDG), a clinical trial consulting firm based in New Haven, Conn.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs